SCGN (Secretagogin) Gene
A calcium-binding protein gene involved in neuroendocrine function and potential biomarker
Gene Information Card
| Symbol | SCGN |
|---|---|
| Full Name | Secretagogin |
| Gene Type | Protein coding |
| Chromosomal Location | 6p22.3 |
| NCBI Gene ID | 10590 ncbi.nlm.nih.gov/gene/10590 |
| Ensembl ID | ENSG00000112319 |
| UniProt ID | O76038 |
| OMIM ID | 604875 |
| HGNC ID | 10590 |
| Aliases | SECRET, SEGN, CALBL |
Description
SCGN encodes secretagogin, a calcium-binding protein belonging to the EF-hand superfamily. It is predominantly expressed in neuroendocrine tissues and plays a role in calcium-dependent signal transduction, exocytosis, and neuroendocrine cell function. Secretagogin is implicated in insulin secretion, neuronal differentiation, and has been studied as a biomarker for various cancers and neurological disorders.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Diabetes mellitus type 2 | Secretagogin is involved in insulin secretion; altered expression may impair beta-cell function | PMID: 19151718 |
| Pancreatic neuroendocrine tumors | Overexpression of SCGN is used as an immunohistochemical marker for neuroendocrine differentiation | PMID: 23348050 |
| Colorectal cancer | SCGN expression is upregulated and associated with tumor progression and poor prognosis | PMID: 25944712 |
| Alzheimer's disease | Reduced SCGN expression in brain regions may contribute to calcium dyshomeostasis and neurodegeneration | PMID: 26901494 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Pancreas | 112.3 | High |
| Brain (cerebral cortex) | 45.6 | Medium |
| Adrenal gland | 38.2 | Medium |
| Testis | 22.1 | Low |
| Lung | 5.4 | Not detected |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HeLa | 0.2 | Not detected |
| HEK 293 | 0.1 | Not detected |
| SH-SY5Y | 12.5 | Low |
| INS-1 (beta-cell) | 89.7 | High |
| MCF7 | 0.3 | Not detected |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.437C>T (p.Pro146Leu) | Missense | <0.01% | Unknown functional effect |
| c.682G>A (p.Glu228Lys) | Missense | <0.01% | Unknown functional effect |
| c.103delC (p.Leu35Trpfs*12) | Frameshift | <0.01% | Predicted loss of function |
Mutation functional classification
Loss of Function (LOF)
Frameshift mutations (e.g., c.103delC) are predicted to cause loss of function due to premature truncation.
Gain of Function (GOF)
No gain-of-function mutations have been reported for SCGN.
Dominant Negative (DN)
No dominant-negative mutations have been described for SCGN.
View complete mutation data：
Gene Ontology (GO)
| • calcium ion binding (GO:0005509) | • dynein complex (GO:0030286) |
| • exocytosis (GO:0006887) | • insulin secretion (GO:0030073) |
| • cytoplasm (GO:0005737) |
Pathways
• Calcium signaling pathway (KEGG: hsa04020)
• Insulin secretion (KEGG: hsa04911)
Protein Summary
Secretagogin is a 276-amino acid calcium-binding protein with six EF-hand domains. It is predominantly expressed in neuroendocrine cells, where it modulates calcium-dependent exocytosis and hormone secretion. The protein interacts with SNARE complex components and may regulate neurotransmitter release. Secretagogin also acts as a molecular chaperone and is involved in neuronal development and survival. Its expression is frequently altered in neuroendocrine tumors and neurodegenerative diseases, making it a potential diagnostic and prognostic biomarker.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| SCGN Knockout HEK293 Cell Line | EDJ-KQ50990 | Human | 10590 | Details Get a Quote |
| SCGN Knockout HeLa Cell Line | EDJ-KQ55439 | Human | 10590 | Details Get a Quote |
| SCGN Knockout A-549 Cell Line | EDJ-KQ63919 | Human | 10590 | Details Get a Quote |
| SCGN Knockout HCT 116 Cell Line | EDJ-KQ72377 | Human | 10590 | Details Get a Quote |
